Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
22 Cards in this Set
- Front
- Back
|
Targeted Therapy |
|
|
|
Human EGFR Family |
erbB1, erbB2, erbB3 (no RTK activity), erbB4
erbB1 = HER1, EGFR erbB2 = HER2, neu erbB3 = HER3 erbB4 = HER4 |
|
|
EGFR antagonist |
-예: Cetuximab, Trastuzumab, Pantimumab
|
|
|
Cetuximab |
-EGFR1 targeting -Colon, H&N cancer -used in comb with chemo & radiation -KRAS mutation: important prognostic factor (KRAS 없는 사람한테 약이 더 잘 든다) -IV infusion |
|
|
Trastuzumab (aka Herceptin) |
-HER2 targeting -Breast cancer -IV infusion. -30 % 의 HER2 positive cancer breast cancer 에 매우 효과적이다. |
|
|
Panitumumab |
-EGFR1 targeting -Metastatic colorectal cancer 에 사용/monotherapy 가능. |
|
|
Lapatinib (TKI) |
-works inside the cell: targeting both ErbB1 & ErbB2.
|
|
|
Non Receptor Tyrosine Kinase (Src/ABL) |
-Philadelphia chromosome: section of chromosome 22 breaks off and translocates to chromosome 9 --> formation of Bcr/Abl -Inhibitor: Imatinib |
|
|
Imatinib (aka Gleevec) |
-TKI -GIST (Gastrointestinal stromal tumors) with cKIT positive; Ph+ CML, Ph+ ALL -administration: Oral |
|
|
Nilotonib |
-modification of imatinib structure to allow tighter binding -TKI inhibitor -Ph+ CML in chronic/accelerated phase -administration: Oral |
|
|
Dasatinib |
-Src/Abl inhibitor -CMLs that are resistant to imatinib -administration: Oral |
|
|
Gefitinib |
-loclly advanced stage or metastatic NSCLC -oral |
|
|
Erlotinib |
-TKI -locally advanged or metastatic NSCLC |
|
|
Lapatinib |
-ErbB1 and ErbB2 TKI -HER2 overexpressing advanced or metastatic breast cancer -Oral administration. |
|
|
VEGF targeting drugs |
|
|
|
Bevacizumab |
-anti-VEGF monoclonal antibody -Metastatic colorectal cancer, NSCLC, HER2 negative breeast cancer, glioblastoma, RCC. -Oral with food. -Serious ophthalmic adverse effect + rebound 로 혈관 생성 |
|
|
Sunitinib |
-VEGFR TK inhibitor -GIST resistant to imatinib; advanced RCC |
|
|
Sorafenib |
-multitarget TKI -Advanced RCC, HCC. |
|
|
Bortezomib |
-26S proteasome inhibitor -multiple myeloma/relapsed lymphoma -rapid IV |
|
|
ATRA (all-trans-retinoic acid) |
-targets the PML-RAR fusion protein -acute promyelocytic leukemia (APL) |
|
|
Bexarotene |
-A synthetic retinoid X receptor (RXR) ligand -cutaneous T cell lymphoma |
|
|
Vorinostat |
-Histone Deacetylase Inhibitor -Progressive, persistent T-cell lymphoma 에 사용. |
